Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.48 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL148087 | 0.84 | TLR7 (0.57) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL145828 | 0.83 | TLR7 (0.48) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL31072343 | 0.83 | TLR7 (0.48) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL31658238 | 0.83 | TLR7 (0.46) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL144931 | 0.82 | TLR7 (0.53) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL31379717 | 0.82 | TLR7 (0.53) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL5808535 | 0.82 | TLR7 (0.55) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL147570 | 0.81 | TLR7 (0.54) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL29551159 | 0.81 | TLR7 (0.54) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL20836817 | 0.81 | TLR7 (0.50) | TLR7TLR8NUDT1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4183412-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GlaxoSmithKline Biologicals S.A. (BE) | 2023-05-24 | — | — | EP | disclosed |
| EP-4144368-A1 | RSV IMMUNIZATION REGIMEN | GlaxoSmithKline Biologicals S.A. (BE) | 2023-03-08 | — | — | EP | disclosed |
| EP-3988115-A2 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GlaxoSmithKline Biologicals S.A. (BE) | 2022-04-27 | — | — | EP | disclosed |
| EP-2368572-B1 | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture | SEQIRUS UK LTD (GB) | 2020-03-04 | — | — | EP | disclosed |
| EP-3527224-A1 | RSV IMMUNIZATION REGIMEN | GlaxoSmithKline Biologicals S.A. (BE) | 2019-08-21 | — | — | EP | disclosed |
| CN-103842374-A | Pre-fusion rsv f antigens | NOVARTIS AG | 2014-06-04 | — | — | CN | disclosed |
| EP-2667892-A1 | RSV IMMUNIZATION REGIMEN | Novartis AG (CH) | 2013-12-04 | — | — | EP | disclosed |
| CN-101111261-B | Saccharide conjugate vaccines | NOVARTIS VACCINES & DIAGNOSTIC | 2013-03-27 | — | — | CN | disclosed |
| CN-102639147-A | RSV F protein compositions and methods of making same | NOVARTIS AG | 2012-08-15 | — | — | CN | disclosed |
| WO-2012103361-A1 | RSV IMMUNIZATION REGIMEN | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| CN-101443039-A | Compositions and methods for immunization with CD1D ligands | NOVARTIS VACCINES & DIAGNOSTIC (IT) | 2009-05-27 | — | — | CN | disclosed |
| CN-101111261-A | Saccharide conjugate vaccines | CHIRON SRL (IT) | 2008-01-23 | — | — | CN | disclosed |